


Cilazapril monohydrate

Cat. No.:	HY-A0043A		
CAS No.:	92077-78-6		
Molecular Formula:	C ₂₂ H ₃₃ N ₃ O ₆		
Molecular Weight:	435.51		
Target:	Angiotensin-converting Enzyme (ACE)		
Pathway:	Metabolic Enzyme/Protease		
Storage:	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	2 years
		-20°C	1 year



SOLVENT & SOLUBILITY

In Vitro

DMSO : ≥ 100 mg/mL (229.62 mM)
 0.1 M NaOH : 14.29 mg/mL (32.81 mM; ultrasonic and warming and adjust pH to 10 with NaOH and heat to 60°C)
 * "≥" means soluble, but saturation unknown.

Preparing Stock Solutions	Solvent Concentration	Mass		
		1 mg	5 mg	10 mg
	1 mM	2.2962 mL	11.4808 mL	22.9616 mL
	5 mM	0.4592 mL	2.2962 mL	4.5923 mL
	10 mM	0.2296 mL	1.1481 mL	2.2962 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo

- Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline
Solubility: ≥ 3 mg/mL (6.89 mM); Clear solution
- Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)
Solubility: ≥ 3 mg/mL (6.89 mM); Clear solution
- Add each solvent one by one: 10% DMSO >> 90% corn oil
Solubility: ≥ 3 mg/mL (6.89 mM); Clear solution

BIOLOGICAL ACTIVITY

Description

Cilazapril Monohydrate is a angiotensin-converting enzyme (ACE) inhibitor used for the treatment of hypertension and congestive heart failure. Target: ACE. Cilazapril is a new nonthiol group containing angiotensin converting enzyme (ACE) inhibitor. Cilazapril has been investigated in more than 4000 patients with all degrees of hypertension, as well as in the special patient groups such as the elderly, renally impaired, and patients with concomitant diseases, such as congestive cardiac failure or chronic obstructive pulmonary disease [1]. Cilazapril is a very potent and highly effective converting

enzyme inhibitor. Doses well below 5 mg/day will probably suffice for therapeutic efficacy [2].

CUSTOMER VALIDATION

- Patent. US20230090708A1.

See more customer validations on www.MedChemExpress.com

REFERENCES

[1]. Szucs, T., Cilazapril. A review. *Drugs*, 1991. 41 Suppl 1: p. 18-24.

[2]. Nussberger, J., et al., Repeated administration of the converting enzyme inhibitor cilazapril to normal volunteers. *J Cardiovasc Pharmacol*, 1987. 9(1): p. 39-44.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA